Inhibition of Bcr-Abl was reported to result in downregulation of STAT3 via JAK and MEK pathways [36], and ponatinib has been reported to inhibit phosphorylation of JAK2 both in BaF3/T315I cells in vitro and in leukemia models in vivo [37]. The gene discussed is STAT3; the disease is leukemia.